Your Article Summary
Austrian Patent Office Rules in Pfizer's Favor, Ranbaxy Product Would Infringe Basic Lipitor Patent
Corporate News Releases - The Healthcare Sales & Marketing Network, 10/18/06
Pfizer said today that the Austrian Patent Office has ruled that a claim in the company's basic patent covering the use of atorvastatin, the active ingredient in Lipitor, would be infringed by generic manufacturer Ranbaxy. Ranbaxy can appeal the ruling, but the patent will remain in effect during the appeals process. Lipitor is sold in Austria under the brand name Sortis
Today in Regulatory Issues...keeping you current
Receive free subspecialty "5-minute updates" via email
Retigabine Regulatory Update
GlaxoSmithKline, 11/03/09
New Drug Application Filed for Eldecalcitol, An Active Vitamin D3 Derivative
Chugai Pharmaceutical Co., 11/04/09
Trends in prescribing and self-poisoning in relation to UK regulatory authority warnings against use of SSRI antidepressants in under-18-year-olds
British Journal of Clinical Pharmacology, 11/02/09
Article Search
Sponsor


See All



